Galapagos reported EUR2.64B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
argenx SE 6.1B 597.47M Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
Genmab DKK 5.3B 6M Jun/2025
Gilead Sciences USD 19.67B 596M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
GRIFOLS EUR 7.6B 1.96B Jun/2025
Hikma Pharmaceutical USD 2.32B 35M Dec/2024
Incyte USD 4.17B 503.34M Jun/2025
Merck EUR 28.26B 1.64B Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
UCB EUR 10.03B 1.08B Dec/2024
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025